TransCode Therapeutics, Inc.
RNAZ
$7.21
-$0.355-4.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.55% | 55.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.73% | 135.17% | |||
| Operating Income | 37.73% | -135.17% | |||
| Income Before Tax | -104.28% | -154.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -104.28% | -154.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -104.28% | -154.85% | |||
| EBIT | 37.73% | -135.17% | |||
| EBITDA | 37.87% | -136.44% | |||
| EPS Basic | 74.17% | -85.93% | |||
| Normalized Basic EPS | 74.17% | -85.94% | |||
| EPS Diluted | 74.17% | -85.93% | |||
| Normalized Diluted EPS | 74.17% | -85.94% | |||
| Average Basic Shares Outstanding | 690.37% | 37.11% | |||
| Average Diluted Shares Outstanding | 690.37% | 37.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||